70556 AUG 2 2 1997 GP 1800 \$1#/2 DE 9/17/97

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

HU, et als.

Serial No:

08/469,641

Art Unit: 1812

Filed:

June 6, 1995

Examiner: Olsen

For:

HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR 3

Attorney Docket No:

325800-463 PF207

molle idal

Assistant Commissioner of Patents Washington, D.C. 20231

SIR:

Pursuant to 37 C.F.R. 1.56(a), Applicant hereby cites the following documents (copies enclosed) listed on the attached copy of Form PTO-1449 which are believed to be material to the patentability of the above-identified application.

This Information Disclosure Statement is filed in accordance with the paragraph of 37 CFR 1.97 checked below:

09/11/1997 DTHOMAS 00000045 08469641 D1 FC:122 130.00 86 This Information Disclosure Statement is filed:

- (1) Within three months of the filing date of a national application; or
- (2) Within three months of the date of entry of the national stage of an international application; OR
- (3) Before the mailing of a first Office Action on the merits.

No fee or certification is required.

<u>X</u> _1.97(c)	This	Information Disclosure Statement is filed after the period
	specif	fied in paragraph (b) above, but before the mailing date of
	either:	
	(1)	A Final Action under 37 CFR 1.113; OR
	(2)	A Notice of Allowance under 37 CFR 1.311; AND is
		accompanied by either:(check one)
		the Certification under 37 CFR 1.97(e) as set our below; OR
	<u>X</u> _	the fee of \$130.00 under 37 CFR 1.17(p).
1.97(d)	This l	information Disclosure Statement is filed after the mailing date
	of either:	
	(1)	a Final Action under 37 CFR 1.113; OR
	(2)	a Notice of Allowance under 37 CFR 1.311;
BUT before payment of the Issue Fee; AND is accompanied by:		
	(1)	the Certification under 37 CFR 1.97(e) as set out below;
		AND
	(2)	Petition is hereby made under 37 CFR 1.97(d) for
		consideration of this Information Disclosure Statement;
		AND,
	(3)	A check in the amount of \$ the petition fee set
	out ir	37 CFR 1.17(i).

If this Information Disclosure Statement is being filed under 37 CFR 1.97(c) or 1.97(d), the undersigned Attorney hereby certifies that:

each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in counterpart foreign application not more than three months prior to the filing date of this Statement; or

no item or information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, or to the knowledge of the undersigned Attorney after making reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing date of this Statement.

The Commissioner is authorized to charge payment of any fees associated with this communication or credit any overpayment to Deposit Account No. 030-0678.

Respectfully submitted,

J.G. Mullins, Reg. No. 33,073

CARELLA, BYRNE, BAIN, GILFILLAN,

CECCHI, STEWART & OLSTEIN

6 Becker Farm Road

Roseland, New Jersey 07068

Tel: (201) 994-1700 Fax: (201) 994-1744